Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 9/20 | 0.52 |
| ▸ | PARP6 | Q2NL67 | 7/20 | 0.52 |
| ▸ | PARP3 | Q9Y6F1 | 7/20 | 0.52 |
| ▸ | TNKS | O95271 | 5/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.39 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.38 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29397384 | 1.00 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TNKS | |
| Hydrochloric Acid SCHEMBL29396179 | 0.99 | PARP1 (0.51) | PARP1PARP2PARP6PARP3TNKS | |
| Hydrochloric Acid SCHEMBL30663255 | 0.99 | PARP1 (0.51) | PARP1PARP2PARP6PARP3TNKS | |
| Hydrochloric Acid SCHEMBL30218644 | 0.91 | PARP1 (0.45) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL30212738 | 0.84 | PARP1 (0.51) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL22912765 | 0.83 | PARP1 (0.51) | PARP1PARP2PARP6PARP3TNKS | |
| Hydrochloric Acid SCHEMBL25235124 | 0.82 | PARP1 (0.50) | PARP1PARP2PARP6PARP3TNKS | |
| Hydrochloric Acid SCHEMBL29394088 | 0.82 | PARP1 (0.50) | PARP1PARP2PARP6PARP3TNKS | |
| Hydrochloric Acid SCHEMBL30413981 | 0.82 | PARP1 (0.50) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL22912735 | 0.82 | PARP1 (0.48) | PARP1PARP2PARP6PARP3TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118317793-A | Methods for treating brain tumors and neuroblastomas | 阿斯利康(瑞典)有限公司 | 2024-07-09 | — | — | CN | disclosed |
| EP-4326720-A1 | PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117177972-A | PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230372527-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2023-11-23 | — | — | US | disclosed |
| US-20230372527-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2023-11-23 | — | — | US | disclosed |
| US-11795158-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2023-10-24 | — | — | US | disclosed |
| US-11795158-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2023-10-24 | — | — | US | disclosed |
| WO-2023118085-A1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | ASTRAZENECA AB (SE) | 2023-06-29 | — | — | WO | disclosed |
| CN-116348115-A | Combination of antibody-drug conjugate and PARP1 selective inhibitor | 阿斯利康(英国)有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| CN-115768760-A | Quinoxaline derivatives as anti-cancer agents | 阿斯利康(瑞典)有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11325906-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2022-05-10 | — | — | US | disclosed |
| WO-2022074617-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| US-20220009901-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2022-01-13 | — | — | US | disclosed |
| WO-2021260092-A1 | QUINOXALINE DERIVATIVES AS ANTI-CANCER DRUGS | ASTRAZENECA AB (SE) | 2021-12-30 | — | — | WO | disclosed |
| US-20210040084-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| WO-2021013735-A1 | PARP1 INHIBITORS | ASTRAZENECA AB (SE) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040084-A1 | CHEMICAL COMPOUNDS | CYP11B2, CYP11B1, CYP4B1 | PARP1 399/4885PARP2 586/4885PARP6 600/4885 |
| US-11795158-B2 | Chemical compounds | CYP11B2, CYP11B1, CYP4B1 | PARP1 399/4885PARP2 586/4885PARP6 600/4885 |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | PARP1 1/4885PARP2 5/4885PARP6 11/4885 |
| US-20220009901-A1 | CHEMICAL COMPOUNDS | CYP11B2, CYP11B1, CYP4B1 | PARP1 399/4885PARP2 586/4885PARP6 600/4885 |
| US-20230372527-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | PARP12, PARP11, PARP1 | PARP1 3/4885PARP2 8/4885PARP6 11/4885 |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | PARP1 1/4885PARP2 5/4885PARP6 11/4885 |
| US-11325906-B2 | Chemical compounds | CYP11B2, CYP11B1, CYP4B1 | PARP1 399/4885PARP2 586/4885PARP6 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.